Cognition Therapeutics, Inc.

NASDAQ:CGTX

Biotechnology

Healthcare
$0.60 -0.70%

-$0.01 today

Market cap
$57.06M
Beta
1.75
P/E (TTM)
-6.4
EPS (TTM)
-$0.22
52W Low $0.25High $3.83

Volume 0.34M

Average 1.23M

CGTX Net Income

Bottom-line profit after all expenses, interest, and taxes.

Cognition Therapeutics, Inc.NASDAQ: CGTX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$4.57M, compared with -$8.48M a year earlier. Trailing-twelve-month net income was -$19.58M.

Context

  • Net income increased in 1 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 2 analysts of -$32.22M (-37.2%) for the fiscal year ending Dec 2026, a slowdown from the +30.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$4.57M-36.7% QoQ
Last fiscal yearDec 2025
-$23.49M+30.9% YoY
LTMMar 2026
-$19.58M+41.2% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+46.1%+17.2%-28.9 pp
1 year+30.9%-37.2%-68.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(23.49M) USD
Year-over-year change
+30.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CGTX compares with its peers on the latest reported figures

  • CGTX's LTM Mar 2026 net income of -$19.58M is the 3rd highest of the 8 companies compared; the peer median is -$46.9M.
  • Its year-over-year change of +41.2% is the 3rd highest of 8, against a peer median of -35.5%.
CGTX Competitors Peer median
Net Income for CGTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGENAgenus Inc.LTM Mar 2026$64.61M +133.9%—52.2%
SPROSpero Therapeutics, Inc.LTM Mar 2026$15.24M +121.8%—27.8%
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$19.58M +41.2%——
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026-$21.76M -35.5%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$46.9M -164.3%—4088.8%
SEERSeer, Inc.LTM Mar 2026-$70.49M +17.9%—468.7%
IRDOpus Genetics, Inc.LTM Mar 2026-$106.93M -82.4%—892.4%
SRZNSurrozen, Inc.LTM Mar 2026-$342.56M -319.3%—4571.1%
Peer median (excluding CGTX) -$46.9M-35.5%—680.6%

Competitors are the stored peer set for CGTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue0235K000
Gross Profit0(235K)000
Gross Margin—————
Research & Development18.57M30.32M37.2M41.68M37.19M
Selling, General & Admin10.03M13.23M13.53M12.29M10.61M
Operating Expenses28.6M43.32M50.72M53.97M47.8M
Depreciation & Amortization93K235K252K266K228K
EBITDA(10.73M)(21.13M)(25.51M)(33.68M)(23.25M)
EBITDA Margin—————
Operating Income(28.6M)(43.55M)(50.72M)(53.97M)(47.8M)
Operating Margin—————
Interest Income17.45M22.22M24.81M00
Interest Expense893K28K27K25K13K
Other Income / Expenses16.88M22.15M24.94M20M24.31M
Income Before Tax(11.72M)(21.4M)(25.79M)(33.97M)(23.49M)
Pre-Tax Margin—————
Income Tax Expense0(22.15M)000
Net Income(11.72M)757K(25.79M)(33.97M)(23.49M)
Net Margin—————
EPS (Basic)(0.73)(0.74)(0.86)(0.85)(0.32)
EPS (Diluted)(0.73)(0.74)(0.86)(0.85)(0.32)
Weighted Avg Shares22.23M28.99M29.99M39.73M72.77M
Weighted Avg Shares (Diluted)22.23M28.99M30.03M39.73M72.77M

Cognition Therapeutics, Inc.

NASDAQ:CGTX

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.